2016 Pipeline of Head and neck Cancer Market Covering 151 Companies

RnRMarketResearch.com adds Head and neck Cancer Pipeline Market to its database.

Pune, India – May 26, 2016 /MarketersMedia/ —

Head and neck Cancer Pipeline Companies Involved in Therapeutics Development are 4SC AG, AB Science SA, AbbVie Inc., Acceleron Pharma, Inc., Advaxis, Inc., Alchemia Limited, Altor BioScience Corporation, Ambrx, Inc., Amgen Inc., ANP Technologies, Inc., arGEN-X BV, ArQule, Inc., Astellas Pharma Inc., AstraZeneca Plc, Atara Biotherapeutics, Inc., ATLAB Pharma SAS, AVEO Pharmaceuticals, Inc., Bayer AG, Betta Pharmaceuticals Co. Ltd., Bexion Pharmaceuticals, LLC., Bio-Path Holdings, Inc., BioDiem Ltd, Biomics Biotechnologies Co., Ltd., Bionovis SA, Biotest AG, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, CEL-SCI Corporation, Celgene Corporation, Cell Medica Limited, Cellceutix Corporation, Celldex Therapeutics, Inc., Celltrion, Inc., Centrose LLC, Corvus Pharmaceuticals, Inc., Cristal Therapeutics B.V., Critical Outcome Technologies Inc., CTI BioPharma Corp., CytomX Therapeutics, Inc., Daiichi Sankyo Company, Limited, Debiopharm International SA, Eisai Co., Ltd., Eli Lilly and Company, EntreChem, S.L., Etubics Corporation, Eureka Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., G&E Herbal Biotechnology Co., Ltd., Genelux Corporation, Genentech, Inc., Genexine, Inc., Genmab A/S, Genticel S.A., GlaxoSmithKline Plc, Gliknik, Inc., Glycotope GmbH, Green Cross Corporation, Hanmi Pharmaceuticals, Co. Ltd., HEC Pharm Co., Ltd., Horizon Pharma Plc, Hutchison MediPharma Limited, Ignyta, Inc., Immune Design Corp., Immunomedics, Inc., Immunovaccine, Inc., Immunovative Therapies, Ltd., Incuron, LLC, Incyte Corporation, Innate Pharma S.A., Inovio Pharmaceuticals, Inc., InteRNA Technologies B.V., IRX Therapeutics, Inc., ISA Pharmaceuticals B.V., ISU ABXIS Co.,Ltd., Jiangsu Kanion Pharmaceutical Co., Ltd., Johnson & Johnson, Kite Pharma, Inc., Kolltan Pharmaceuticals, Inc., Laboratoires Pierre Fabre SA, Loxo Oncology, Inc., Lytix Biopharma AS, Mabion SA, Mabtech Limited, MacroGenics, Inc., Marsala Biotech Inc., Meabco A/S, MedImmune, LLC, Merck & Co., Inc., Merck KGaA, Merrimack Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Mirati Therapeutics Inc., Molecular Partners AG, Molplex Ltd., Multimmune GmbH, NanoCarrier Co., Ltd., Natco Pharma Limited, Northwest Biotherapeutics, Inc., Novartis AG, Omnitura Therapeutics Inc., Oncobiologics, Inc., Oncolys BioPharma Inc., Oncolytics Biotech Inc., Onconova Therapeutics, Inc., OncoSec Medical Incorporated, Ono Pharmaceutical Co., Ltd., Orbis Biosciences, Inc., Oryx GmbH & Co. KG, Otsuka Holdings Co., Ltd., OXiGENE, Inc., Panacea Biotec Limited, PCI Biotech Holding ASA, Pfizer Inc., Pharma Mar, S.A., Pharmacyclics, Inc., Philogen S.p.A., Pique Therapeutics, Plexxikon Inc., PNP Therapeutics, Inc., Profectus BioSciences, Inc., Sanofi, Sapvax, Sareum Holdings Plc, Selecta Biosciences, Inc., Shanghai Henlius Biotech Co., Ltd., Shenzen SiBiono GeneTech Co., Ltd., Shionogi & Co., Ltd., Silence Therapeutics Plc, Sillajen Biotherapeutics, Sinil Pharmaceutical Co., Ltd, Sorrento Therapeutics, Inc., SuviCa Inc., Symphogen A/S, Synta Pharmaceuticals Corp., Taiwan Liposome Company, Ltd., Takara Bio Inc., Takis S.r.l., Teva Pharmaceutical Industries Ltd., Theravectys SA, Threshold Pharmaceuticals, Inc., Tolero Pharmaceuticals, Inc., UbiVac, LLC, Vaccibody AS, VasGene Therapeutics, Inc., VentiRx Pharmaceuticals, Inc., Virttu Biologics Limited, VLPbio, VM Discovery, Inc. and Vyriad.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Inquire more about this research at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=582456

The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects.

Complete research report of 1127 pages with TOC is available at http://www.rnrmarketresearch.com/head-and-neck-cancer-pipeline-review-h1-2016-market-report.html

Scope

– The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer
– The report reviews pipeline therapeutics for Head And Neck Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Head And Neck Cancer therapeutics and enlists all their major and minor projects
– The report assesses Head And Neck Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer

For more information about us, please visit http://www.rnrmarketresearch.com/

Contact Info:
Name: Ritesh Tiwari
Organization: RnR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41

Source: http://marketersmedia.com/2016-pipeline-of-head-and-neck-cancer-market-covering-151-companies/116601

Release ID: 116601